Last updated: April 3, 2026
What is the drug associated with NDC 70377-0129?
The National Drug Code (NDC) 70377-0129 corresponds to Ultragenyx's Mepsevii (vesicular monoamine transporter 2 inhibitor), a rare genetic disorder treatment used for patients with mucopolysaccharidosis VII (MPS VII or Sly syndrome). Mepsevii received FDA approval in 2017.
Market Overview
Rare Disease Context
- Prevalence: Estimated 1 in 1 million live births worldwide. The U.S. population is approximately 330 million, translating to roughly 330 cases.
- Treatment landscape: Limited options; only Mepsevii among approved therapies, with enzyme replacement therapy being a common approach for similar lysosomal storage diseases.
- Pricing rationale: High prices reflect small patient population, complex manufacturing, and high R&D costs.
Competitor Landscape
- No direct FDA-approved competitors specific for MPS VII.
- Investigative therapies: enzyme enhancement approaches and gene therapies are in early development stages.
- Off-label use: None substantially documented due to the rare nature of MPS VII.
Revenue Potential
- Market size: Approximately 330 U.S. patients.
- Estimated annual per-patient price: Between $500,000 and $700,000.
- Total U.S. market potential: $165 million to $231 million, assuming full market penetration.
International Market
- Markets in Europe, Japan, and Canada are smaller but following similar pricing structures.
- Regulatory approval in these regions can expand total global revenue by an estimated 50%.
Price Analysis and Trends
Current List Price
- Average list price: Around $500,000 to $600,000 annually per patient.
- Pricing factors: Raw material costs, manufacturing complexity, small patient population, and development expenses.
- Reimbursement: Insurance and Medicaid negotiate discounts; net prices often 20%-30% lower.
Historical Pricing Trends
- Price increases over the past three years have been in the 3%-5% annual range.
- Price adjustments are driven by inflation, manufacturing costs, and payer negotiations.
Future Price Projections
| Year |
Estimated Price per Patient |
Notes |
| 2023 |
$550,000 |
Current market price |
| 2024 |
$560,000 |
1.8% increase |
| 2025 |
$570,000 |
Continues trend |
| 2026 |
$580,000 |
Slight upward adjustment |
- Price increases are moderate; significant hikes depend on new formulations or approval of adjunct therapies.
Regulatory and Policy Impact
- Price regulation trends focus on rare diseases but remain limited.
- Medicaid and Medicare negotiate drug prices; initiatives like permanent inflation caps are under discussion but not yet implemented.
- Compassionate use and expanded access policies could affect pricing and utilization patterns.
Key Market Drivers
- Lack of alternative therapies.
- Increasing awareness of MPS VII.
- Advances in diagnostics leading to earlier detection.
- Potential approval of gene therapy could affect demand and market dynamics.
Risks and Uncertainties
- Development of gene therapies or other curative approaches could reduce demand for enzyme replacement.
- Changes in reimbursable pricing or healthcare policy could impact revenue.
- Small patient population means high market sensitivity to pricing changes.
Key Takeaways
- NDC 70377-0129 corresponds to Ultragenyx's Mepsevii used for MPS VII.
- The U.S. market comprises fewer than 400 estimated patients.
- Current list prices average around $550,000 annually per patient.
- Total market potential in the U.S. approximates $165 million.
- Price growth is projected to be modest, around 2% annually, barring significant regulatory or therapeutic developments.
FAQs
1. How does pricing for rare disease drugs like NDC 70377-0129 compare globally?
Global prices vary based on healthcare systems, with some countries negotiating discounts tiered to income levels. Europe and Japan typically have lower reimbursed prices than the U.S., often 30%-50% lower.
2. What factors influence the pricing of Mepsevii?
Manufacturing complexity, small patient population, R&D costs, and lack of generic competition drive high prices. Reimbursement negotiations also impact net prices.
3. Could new therapies or gene editing impact MPS VII's market?
Yes. Gene therapies could offer a one-time curative approach, potentially reducing demand for enzyme replacement therapies like Mepsevii.
4. How does payer discounting impact actual revenue?
Payer discounts, such as insurance negotiations, often reduce gross list prices by 20%-30%, affecting net revenues.
5. What opportunities exist for price optimization?
Streamlining manufacturing, increasing market penetration through expanded indications, and value-based contracting could improve revenue outcomes.
References
- U.S. Food and Drug Administration. (2017). FDA approves first drug for Mucopolysaccharidosis VII. FDA.
- IQVIA. (2022). Global Rare Disease Treatment Pricing and Market Size Report.
- EvaluatePharma. (2022). Pharmaceutical Price Trends for Rare Disease Drugs.
- CMS.gov. (2022). Medicaid and Medicare Drug Pricing Policies.
- GlobalData. (2022). Future Trends in Rare Disease Treatment Spending.
